Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF) - Results of a prospective randomised monocentre study

Bone Marrow Transplantation

Volumn 28, Issue 3, 2001, Pages 259-264

  Bonig H ^a   Silbermann, S ^a   Weller, S ^a   Kirschke, R ^a   Korholz D ^b   Janssen, G ^a   Gobel U ^a   Nurnberger W ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cancer; G CSF; Glycosylation; Neutropenia; Pediatric

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; C REACTIVE PROTEIN; CARBOHYDRATE DERIVATIVE; CARBOPLATIN; CD34 ANTIGEN; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DIPYRONE; ETOPOSIDE; GLYCOSYLATED PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; PARACETAMOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THREONINE; TOPOTECAN; VINCRISTINE;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BIOLOGICAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FEVER; HEMATOPOIESIS; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MORBIDITY; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN GLYCOSYLATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; FEMALE; FILGRASTIM; GLYCOSYLATION; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFECTION; LEUKOPENIA; MALE; MATCHED-PAIR ANALYSIS; NEUTROPENIA; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; THERAPEUTIC EQUIVALENCY;

EID: 0034888570     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703136     Document Type: Article

References (36)

1. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients
2. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo
3. Granulocyte colony-stimulating factor potentiates anti-Candida albicans growth inhibitory activity of polymorphonuclear cells
4. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer
5. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy
6. A randomized phase-III study of the efficacy of granulocyte-colony stimulating factor in children with high-risk acute lymphoblastic leukemia
7. Single dose of filgrastim (rhG-CSF) increases the number of hemopoietic progenitors in the peripheral blood of adult volunteers
8. A time course study for optimal harvest of peripheral blood progenitor cells by granulocyte colony-stimulating factor in healthy volunteers
9. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients
10. Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells
11. Filgrastim (r-metHuG-CSF): The first 10 years
12. Structural characterization of natural and recombinant human granulocyte colony-stimulating factors
13. Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells
14. Glycosylation of recombinant human granulocyte colony-stimulating factor: Implications for stability and potency
15. O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity
16. Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim)
17. Influence of the carbohydrate moiety on the stability of glycoproteins
18. Cysteine 17 of recombinant human granulocyte colony-stimulating factor is partially solvent-exposed
19. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects
20. Placebo-controlled phase III trial of lenograstim in bone marrow transplantation
21. Phase I study of in vivo lenograstim (rHuG-CSF) for stem cell collection demonstrates improved neutrophil recovery after autologous bone marrow transplantation
22. Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells
23. Participants of the collaborative study. The international standard for granulocyte colony-stimulating factor (G-CSF). Evaluation in an international collaborative study
24. + cells
25. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats
26. Three types of recombinant human granulocyte colony-stimulating factor have equivalent biological activities in monkeys
27. + cells by glycosylated and nonglycosylated G-CSF in healthy volunteers - A comparative study
28. Crossver study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers
29. + subsets in bone marrow and peripheral blood after priming with glycosylated or non-glycosylated rhG-CSF
30. Mobilization of PBSC for hematological rescue: Comparison between glycosylated and non-glycosylated G-CSF
31. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma
32. Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation
33. + cells in association with modulation of CD44 and CD31 expression during continuous intravenous administration of G-CSF in normal donors
34. Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients
35. The clinical utility of granulocyte colony-stimulating factor: Early achievements and future promise
36. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat